These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://jaysonozkh541597.techionblog.com/39325125/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide